Devonian Health GroupDVHGF 49 Interest Coverage is 0 (At Loss) as of Jan. 2026. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $3.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 377 Biotechnology companies, Devonian Health Group ranks worse than 265251.72% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Devonian Health Group's
Operating Income
for the
three
months ended in Jan. 2026 was $-1.63 Mil. Devonian Health Group's Interest Expense for the
three
months ended in Jan. 2026 was $-0.00 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Devonian Health Group's Interest Coverage or its related term are showing as below:
DVHGF's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07 * Ranked among companies with meaningful Interest Coverage only.
Devonian Health Group (OTCPK:DVHGF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Devonian Health Group Interest Coverage Related Terms
Devonian Health Group Interest Coverage Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
DVHGF vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Devonian Health Group's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Interest Coverage falls into.
Devonian Health Group Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Devonian Health Group did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Devonian Health Group (DVHGF) has a Interest Coverage of 0 (At Loss) as of Jan. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Devonian Health Group and its competitors. According to the industry distribution chart, Devonian Health Group ranks #999999 out of 377 companies in the Biotechnology industry.
Is Devonian Health Group's Interest Coverage too high?
Devonian Health Group's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Devonian Health Group ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #999999 out of 377 companies for Interest Coverage. This places Devonian Health Group in the lower half of its industry. The industry median Interest Coverage is 106.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Devonian Health Group and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.02, compared to a current price of $7.00 — trading 131.8% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Interest Coverage is 0 (At Loss) as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 131.8% above its estimated GF Value™ of $3.02.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
Interest Coverage: 0 (At Loss)
GF Value™: $3.02 vs. price of $7.00 (131.8% above fair value)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score
Get the complete analysis for DVHGF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
